{"id":"ibritumomab-tiuxetan","rwe":[{"pmid":"41746558","year":"2026","title":"Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.","finding":"","journal":"EJNMMI radiopharmacy and chemistry","studyType":"Clinical Study"},{"pmid":"41130791","year":"2025","title":"Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal.","finding":"","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","studyType":"Clinical Study"},{"pmid":"40361339","year":"2025","title":"Assessing the Clinical Effectiveness of Radioimmunotherapy with Combined Radionuclide/Monoclonal Antibody Conjugates in Cancer Treatment: Insights from Randomised Clinical Trials.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"38464386","year":"2024","title":"Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.","finding":"","journal":"Exploration of targeted anti-tumor therapy","studyType":"Clinical Study"},{"pmid":"38207010","year":"2024","title":"A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.","finding":"","journal":"The oncologist","studyType":"Clinical Study"}],"tags":[{"label":"CD20-directed Radiotherapeutic Antibody","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"B-lymphocyte antigen CD20","category":"target"},{"label":"MS4A1","category":"gene"},{"label":"V10XX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Follicular non-Hodgkin's lymphoma","category":"indication"},{"label":"Spectrum Pharms","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":674.219,"date":"","count":112,"signal":"Meningitis tuberculous","source":"DrugCentral FAERS","actionTaken":"Reported 112 times (LLR=674)"},{"llr":246.118,"date":"","count":73,"signal":"Progressive multifocal leukoencephalopathy","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=246)"},{"llr":241.052,"date":"","count":81,"signal":"Myelodysplastic syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=241)"},{"llr":230.319,"date":"","count":151,"signal":"Sepsis","source":"DrugCentral FAERS","actionTaken":"Reported 151 times (LLR=230)"},{"llr":183.03,"date":"","count":130,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 130 times (LLR=183)"},{"llr":144.062,"date":"","count":117,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 117 times (LLR=144)"},{"llr":128.793,"date":"","count":51,"signal":"Acute myeloid leukaemia","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=129)"},{"llr":124.618,"date":"","count":57,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=125)"},{"llr":102.612,"date":"","count":57,"signal":"Mucosal inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=103)"},{"llr":99.635,"date":"","count":25,"signal":"Stem cell transplant","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=100)"},{"llr":91.598,"date":"","count":80,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=92)"},{"llr":75.581,"date":"","count":62,"signal":"Pancytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=76)"},{"llr":64.948,"date":"","count":64,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=65)"},{"llr":62.537,"date":"","count":34,"signal":"Cytomegalovirus infection","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=63)"},{"llr":62.414,"date":"","count":61,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=62)"}],"commonSideEffects":[{"effect":"Meningitis tuberculous","drugRate":"LLR 674","severity":"serious"},{"effect":"Progressive multifocal leukoencephalopathy","drugRate":"LLR 246","severity":"common"},{"effect":"Myelodysplastic syndrome","drugRate":"LLR 241","severity":"common"},{"effect":"Sepsis","drugRate":"LLR 230","severity":"common"},{"effect":"Thrombocytopenia","drugRate":"LLR 183","severity":"common"},{"effect":"Neutropenia","drugRate":"LLR 144","severity":"common"},{"effect":"Acute myeloid leukaemia","drugRate":"LLR 129","severity":"common"},{"effect":"Bone marrow failure","drugRate":"LLR 125","severity":"common"},{"effect":"Mucosal inflammation","drugRate":"LLR 103","severity":"common"},{"effect":"Stem cell transplant","drugRate":"LLR 100","severity":"common"},{"effect":"Pancytopenia","drugRate":"LLR 76","severity":"common"},{"effect":"Disease progression","drugRate":"LLR 65","severity":"common"},{"effect":"Cytomegalovirus infection","drugRate":"LLR 63","severity":"common"},{"effect":"Platelet count decreased","drugRate":"LLR 62","severity":"common"}]},"trials":[],"aliases":[],"company":"Spectrum Pharms","patents":[{"type":"Biologic Exclusivity","filed":"February 19, 2002","source":"FDA Purple Book","status":"Active","expires":"February 19, 2009","territory":"US","patentNumber":"BLA 125019"}],"pricing":[],"allNames":"zevalin","offLabel":[],"synonyms":["ibritumomab tiuxetan (90Y)","ibritumomab tiuxetan","zevalin","IDEC-Y2B8"],"timeline":[{"date":"2002-02-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Spectrum Pharms)"},{"date":"2004-01-16","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"approvals":[{"date":"2002-02-19","orphan":false,"company":"SPECTRUM PHARMS","regulator":"FDA"},{"date":"2004-01-16","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Zevalin","ecosystem":[{"indication":"Follicular non-Hodgkin's lymphoma","otherDrugs":[{"name":"bendamustine","slug":"bendamustine","company":"Cephalon"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"}],"globalPrevalence":123507000}],"mechanism":{"target":"B-lymphocyte antigen CD20","novelty":"Follow-on","targets":[{"gene":"MS4A1","source":"DrugCentral","target":"B-lymphocyte antigen CD20","protein":"B-lymphocyte antigen CD20"}],"moaClass":"CD20-directed Antibody Interactions","modality":"Monoclonal Antibody","drugClass":"CD20-directed Radiotherapeutic Antibody","explanation":"Imagine your body's immune system as a group of soldiers. B cells are like the scouts, searching for and identifying threats. Zevalin is like a guided missile that targets these B cells, delivering a dose of radiation that kills them, helping to treat conditions like non-Hodgkin's lymphoma.","oneSentence":"Zevalin works by binding to CD20 on B cells and delivering a radioactive dose that kills the cells.","technicalDetail":"Zevalin is a monoclonal antibody that targets the CD20 antigen on B cells, which are then selectively irradiated by the attached radioactive isotope, Yttrium-90, resulting in cell death."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan","title":"Ibritumomab tiuxetan","extract":"Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.","wiki_history":"==History==\nDeveloped by IDEC Pharmaceuticals, now part of Biogen Idec, ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the US Food and Drug Administration (FDA) in 2002 to treat cancer. It was approved for the treatment of people with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including people with rituximab refractory follicular NHL. It was given marketing authorization by the European Medicines Agency in 2004 for the treatment of adults with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma but. The authorization lapsed in July 2024, after it wasn't marketed for more than three consecutive years.\n\nIn September 2009, ibritumomab tiuxetan received approval from the FDA for an expanded label to include previously untreated people with a chemotherapy response.","wiki_society_and_culture":"== Society and culture ==\n=== Economics ===\nIbritumomab tiuxetan is under patent protection and not available in generic form. When approved, it was the most expensive medication available given in a single dose, costing over  (€30,000) for the average dose. Compared with other monoclonal antibody treatments (many of which are well over $40,000 for a course of therapy), it may be considered cost effective."},"commercial":{"launchDate":"2002","_launchSource":"DrugCentral (FDA 2002-02-19, SPECTRUM PHARMS)"},"purpleBook":{"bla":"125019","source":"FDA Purple Book","approvalDate":"February 19, 2002","licenseStatus":"Licensed","exclusivityExpiry":"February 19, 2009"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4984","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IBRITUMOMAB%20TIUXETAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IBRITUMOMAB TIUXETAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T13:54:53.907138","biosimilars":[],"competitors":[{"drugName":"sodium phosphate (32P)","drugSlug":"sodium-phosphate-(32p)","fdaApproval":"1959-03-04","relationship":"same-class"},{"drugName":"radium Ra 223 dichloride","drugSlug":"radium-ra-223-dichloride","fdaApproval":"2013-05-15","relationship":"same-class"},{"drugName":"lutetium (177Lu) oxodotreotide","drugSlug":"lutetium-(177lu)-oxodotreotide","fdaApproval":"2018-01-26","relationship":"same-class"},{"drugName":"lutetium (177Lu) vipivotide tetraxetan","drugSlug":"lutetium-(177lu)-vipivotide-tetraxetan","fdaApproval":"2022-03-23","relationship":"same-class"}],"genericName":"ibritumomab tiuxetan","indications":{"approved":[{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":308121000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":123507000,"prevalenceMethod":"curated","prevalenceSource":"J Insur Med, 2023 (PMID:37725503)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sodium-phosphate-(32p)","brandName":"sodium phosphate (32P)","genericName":"sodium phosphate (32P)","approvalYear":"1959","relationship":"same-class"},{"drugId":"radium-ra-223-dichloride","brandName":"radium Ra 223 dichloride","genericName":"radium Ra 223 dichloride","approvalYear":"2013","relationship":"same-class"},{"drugId":"lutetium-(177lu)-oxodotreotide","brandName":"lutetium (177Lu) oxodotreotide","genericName":"lutetium (177Lu) oxodotreotide","approvalYear":"2018","relationship":"same-class"},{"drugId":"lutetium-(177lu)-vipivotide-tetraxetan","brandName":"lutetium (177Lu) vipivotide tetraxetan","genericName":"lutetium (177Lu) vipivotide tetraxetan","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":["Lymphoma"],"enrollment":30,"completionDate":"2010-10"},{"nctId":"NCT02320292","phase":"PHASE3","title":"Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-02-11","conditions":["Ann Arbor Stage I Grade 1 Follicular Lymphoma","Ann Arbor Stage I Grade 2 Follicular Lymphoma","Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage III Grade 1 Follicular Lymphoma","Ann Arbor Stage III Grade 2 Follicular Lymphoma","Ann Arbor Stage IV Grade 1 Follicular Lymphoma","Ann Arbor Stage IV Grade 2 Follicular Lymphoma"],"enrollment":20,"completionDate":"2023-11-09"},{"nctId":"NCT01359592","phase":"PHASE2","title":"S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-09","conditions":["Lymphoma"],"enrollment":159,"completionDate":"2023-12"},{"nctId":"NCT00577278","phase":"PHASE2","title":"A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-10-03","conditions":["Graft Versus Host Disease","Leukemia","Lymphoma"],"enrollment":41,"completionDate":"2023-12-14"},{"nctId":"NCT00031642","phase":"PHASE1,PHASE2","title":"Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-01-01","conditions":["Lymphoma"],"enrollment":26,"completionDate":"2008-03-01"},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":["Relapsed Follicular Lymphoma"],"enrollment":159,"completionDate":"2024-01"},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":["Oncology Patients Receiving Chemotherapy"],"enrollment":34,"completionDate":"2020-12-23"},{"nctId":"NCT00168727","phase":"PHASE4","title":"Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Biogen","startDate":"2003-06-01","conditions":["Lymphoma, Non-Hodgkin","Lymphoma, Low-Grade"],"enrollment":12,"completionDate":"2005-10-31"},{"nctId":"NCT01811368","phase":"PHASE2","title":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Joseph Tuscano","startDate":"2013-03-12","conditions":["Refractory Non Hodgkin Lymphoma","Relapsed Non Hodgkin Lymphoma"],"enrollment":20,"completionDate":"2023-12"},{"nctId":"NCT00493467","phase":"PHASE2","title":"Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-06","conditions":["Lymphoma"],"enrollment":31,"completionDate":"2022-08-11"},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":["Follicular Non-Hodgkin's Lymphoma"],"enrollment":807,"completionDate":"2021-12"},{"nctId":"NCT00290511","phase":"PHASE2","title":"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06-29","conditions":["Lymphoma"],"enrollment":49,"completionDate":"2021-02-12"},{"nctId":"NCT00322218","phase":"PHASE3","title":"Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-05","conditions":["Lymphoma, Large Cell, Diffuse"],"enrollment":68,"completionDate":"2008-12"},{"nctId":"NCT00384111","phase":"PHASE3","title":"Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-10","conditions":["Follicular Lymphoma","Lymphoma, Follicular"],"enrollment":26,"completionDate":"2008-11"},{"nctId":"NCT00070018","phase":"PHASE2","title":"S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-02","conditions":["Lymphoma"],"enrollment":46,"completionDate":"2015-01-08"},{"nctId":"NCT00637832","phase":"PHASE2","title":"Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"University of Southampton","startDate":"2008-04-01","conditions":["Lymphoma"],"enrollment":1,"completionDate":"2015-01-06"},{"nctId":"NCT01510184","phase":"PHASE3","title":"Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-04-19","conditions":["Diffuse Large B-cell Lymphoma","Follicle Center Lymphoma"],"enrollment":79,"completionDate":"2014-10-23"},{"nctId":"NCT01662102","phase":"PHASE3","title":"Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-12-11","conditions":["Follicular Lymphoma"],"enrollment":1,"completionDate":"2013-03-05"},{"nctId":"NCT01549886","phase":"PHASE2","title":"Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2011-11","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":5,"completionDate":"2015-05"},{"nctId":"NCT01448928","phase":"","title":"Zevalin Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2008-09","conditions":["Non-Hodgkin's Lymphoma (NHL)"],"enrollment":400,"completionDate":"2018-01-31"},{"nctId":"NCT01434472","phase":"PHASE2","title":"High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11-16","conditions":["Post-Transplant Lymphoproliferative Disorder","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Burkitt Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":20,"completionDate":"2020-05-06"},{"nctId":"NCT00562978","phase":"PHASE1,PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-05-16","conditions":["Lymphoma"],"enrollment":54,"completionDate":"2018-05-21"},{"nctId":"NCT01234766","phase":"PHASE2","title":"Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-10","conditions":["Lymphoma, Follicular"],"enrollment":39,"completionDate":"2021-04-01"},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":["Diffuse Large Cell Lymphoma","Lymphoma"],"enrollment":30,"completionDate":"2020-03-05"},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2019-11-14"},{"nctId":"NCT00491491","phase":"PHASE3","title":"Zevalin-beam for Aggressive Lymphoma","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2007-06","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":60,"completionDate":"2015-02"},{"nctId":"NCT01973062","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-03","conditions":["Primary Central Nervous System Non-Hodgkin Lymphoma"],"enrollment":1,"completionDate":"2015-06"},{"nctId":"NCT00889798","phase":"","title":"Tumor Registry of Lymphatic Neoplasia","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-04","conditions":["Non-Hodgkin's Lymphoma (NHL)","Chronic Lymphocytic Leukemia (CLL)","Multiple Myeloma (MM)"],"enrollment":3795,"completionDate":"2019-08-31"},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":["Leukemia","Lymphoma"],"enrollment":20,"completionDate":"2019-04-24"},{"nctId":"NCT00662948","phase":"PHASE2","title":"ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2008-12","conditions":["Lymphoma"],"enrollment":149,"completionDate":"2017-10-30"},{"nctId":"NCT00582166","phase":"PHASE2","title":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01-25","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":18,"completionDate":"2013-03"},{"nctId":"NCT01493479","phase":"PHASE2","title":"Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2007-06-06","conditions":["Follicular Lymphoma"],"enrollment":76,"completionDate":"2015-11-06"},{"nctId":"NCT00372905","phase":"PHASE1,PHASE2","title":"Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2007-07-24","conditions":["Lymphoma"],"enrollment":18,"completionDate":"2013-07-08"},{"nctId":"NCT00732498","phase":"PHASE2","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2006-05-15","conditions":["Lymphoma"],"enrollment":28,"completionDate":"2018-10-15"},{"nctId":"NCT00089284","phase":"PHASE1,PHASE2","title":"Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-10-28","conditions":["Non-Hodgkin's Lymphoma (NHL)"],"enrollment":30,"completionDate":"2008-08-20"},{"nctId":"NCT00392691","phase":"PHASE1","title":"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-10","conditions":["Lymphoma"],"enrollment":20,"completionDate":"2013-05"},{"nctId":"NCT01686165","phase":"PHASE2","title":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2012-08-31","conditions":["Anaplastic Large Cell Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Mantle Cell Lymphoma"],"enrollment":5,"completionDate":"2017-11-09"},{"nctId":"NCT00416312","phase":"","title":"Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-07","conditions":["Lymphoma"],"enrollment":9,"completionDate":"2009-10"},{"nctId":"NCT00012298","phase":"PHASE1,PHASE2","title":"Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":["Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Splenic Marginal Zone Lymphoma","Waldenström Macroglobulinemia"],"enrollment":81,"completionDate":"2010-04"},{"nctId":"NCT00695409","phase":"PHASE2","title":"Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-18","conditions":["Lymphoma"],"enrollment":122,"completionDate":"2017-03-27"},{"nctId":"NCT00119392","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-06","conditions":["B-cell Chronic Lymphocytic Leukemia","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Splenic Marginal Zone Lymphoma","Waldenström Macroglobulinemia"],"enrollment":42,"completionDate":"2016-04-23"},{"nctId":"NCT00477815","phase":"PHASE1","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-05-31","conditions":["Multiple Myeloma and Plasma Cell Neoplasm"],"enrollment":30,"completionDate":"2018-05-07"},{"nctId":"NCT02366663","phase":"PHASE3","title":"BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2015-01","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":3,"completionDate":"2016-10"},{"nctId":"NCT00689169","phase":"PHASE2","title":"Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2007-08","conditions":["Lymphoma, Large Cell, Diffuse"],"enrollment":75,"completionDate":"2014-01"},{"nctId":"NCT00073957","phase":"PHASE2","title":"Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2003-12","conditions":["Lymphoma"],"enrollment":25,"completionDate":"2012-01-01"},{"nctId":"NCT00110149","phase":"PHASE2","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-05","conditions":["Lymphoma"],"enrollment":12,"completionDate":"2015-03"},{"nctId":"NCT00088881","phase":"PHASE2","title":"Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12","conditions":["Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Splenic Marginal Zone Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia"],"enrollment":62,"completionDate":"2011-03"},{"nctId":"NCT00644371","phase":"PHASE2","title":"Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2007-11","conditions":["Non-Hodgkin Lymphoma"],"enrollment":20,"completionDate":"2013-02-04"},{"nctId":"NCT01207765","phase":"PHASE2","title":"Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2008-04","conditions":["Multiple Myeloma"],"enrollment":8,"completionDate":"2013-06"},{"nctId":"NCT00334438","phase":"PHASE1","title":"Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-07","conditions":["Lymphoma"],"enrollment":12,"completionDate":"2011-10"},{"nctId":"NCT02992223","phase":"","title":"Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2014-07","conditions":["Refractory B-Cell Non-Hodgkin Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma"],"enrollment":58,"completionDate":"2015-07"},{"nctId":"NCT00607854","phase":"PHASE2","title":"Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2008-02","conditions":["Diffuse Large B-Cell Lymphoma","Mantle Cell Lymphoma"],"enrollment":31,"completionDate":"2011-11"},{"nctId":"NCT00062114","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-04","conditions":["Lymphoma"],"enrollment":84,"completionDate":"2007-04"},{"nctId":"NCT01446562","phase":"PHASE2","title":"Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-05","conditions":["Follicular Lymphoma"],"enrollment":34,"completionDate":"2016-05"},{"nctId":"NCT00761384","phase":"PHASE1,PHASE2","title":"High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2008-04","conditions":["B-cell Lymphoma"],"enrollment":7,"completionDate":"2016-01"},{"nctId":"NCT00336843","phase":"PHASE2","title":"Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2005-11","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":19,"completionDate":"2010-05"},{"nctId":"NCT00414089","phase":"PHASE2","title":"Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL","status":"WITHDRAWN","sponsor":"AHS Cancer Control Alberta","startDate":"","conditions":["Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00646750","phase":"PHASE2","title":"Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2008-01","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":31,"completionDate":"2012-06"},{"nctId":"NCT00438880","phase":"PHASE1,PHASE2","title":"Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-10","conditions":["Adult Non-Hodgkin Lymphoma","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Nodal Marginal Zone Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Splenic Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia"],"enrollment":38,"completionDate":"2014-11"},{"nctId":"NCT00310128","phase":"PHASE2","title":"Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma","status":"WITHDRAWN","sponsor":"AIDS Malignancy Consortium","startDate":"2006-02","conditions":["AIDS-related Lymphoma","Adult Non-Hodgkin's Lymphoma","Anaplastic Large Cell Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00453102","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":["Marginal Zone Lymphoma"],"enrollment":18,"completionDate":"2015-02"},{"nctId":"NCT00005592","phase":"PHASE2","title":"Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"1999-11","conditions":["Lymphoma"],"enrollment":23,"completionDate":"2005-11"},{"nctId":"NCT01497275","phase":"PHASE2","title":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2012-02","conditions":["Mantle-Cell Lymphoma"],"enrollment":5,"completionDate":"2014-05"},{"nctId":"NCT00319332","phase":"PHASE3","title":"A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":["Lymphoma, Small Cleaved-Cell, Follicular","Lymphoma, Large-Cell, Follicular","Lymphoma, Follicular","Lymphoma, Non-Hodgkin"],"enrollment":0,"completionDate":"2021-02"},{"nctId":"NCT00440583","phase":"PHASE2","title":"The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2006-09","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":15,"completionDate":"2012-05"},{"nctId":"NCT00220285","phase":"PHASE2","title":"Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-08","conditions":["Non-Hodgkin's Lymphoma","Lymphoma, B-Cell","Lymphoma, Low-Grade"],"enrollment":45,"completionDate":"2005-10"},{"nctId":"NCT01538472","phase":"PHASE1,PHASE2","title":"Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":["Lymphoma"],"enrollment":40,"completionDate":"2011-11"},{"nctId":"NCT00302757","phase":"PHASE1,PHASE2","title":"Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2006-03","conditions":["Non-Hodgkin Lymphoma"],"enrollment":60,"completionDate":"2011-07"},{"nctId":"NCT01130194","phase":"PHASE2","title":"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2006-07","conditions":["Follicular Lymphoma"],"enrollment":29,"completionDate":"2012-06"},{"nctId":"NCT00119730","phase":"PHASE2","title":"Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-02","conditions":["Mantle Cell Lymphoma"],"enrollment":30,"completionDate":"2013-12"},{"nctId":"NCT00070447","phase":"PHASE2","title":"Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-11","conditions":["Lymphoma"],"enrollment":0,"completionDate":"2006-06"},{"nctId":"NCT00033423","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2001-08","conditions":["Lymphoma"],"enrollment":18,"completionDate":"2009-05"},{"nctId":"NCT00387023","phase":"NA","title":"Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-02","conditions":["Non-Hodgkin's Lymphoma","Lymphoma"],"enrollment":12,"completionDate":"2012-07"},{"nctId":"NCT00048737","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-10","conditions":["Lymphoma","Leukemia"],"enrollment":70,"completionDate":"2011-12"},{"nctId":"NCT00493454","phase":"PHASE2","title":"Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-04","conditions":["Lymphoma"],"enrollment":6,"completionDate":"2011-03"},{"nctId":"NCT00521560","phase":"PHASE2","title":"A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2006-03","conditions":["Primary Non-Hodgkin-Lymphoma","Refractory Non-Hodgkin-Lymphoma","CD20+ Aggressive Non-Hodgkin's Lymphoma"],"enrollment":28,"completionDate":"2012-08"},{"nctId":"NCT00064246","phase":"PHASE1,PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-07","conditions":["Post-transplant Lymphoproliferative Disorder","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Waldenström Macroglobulinemia"],"enrollment":28,"completionDate":""},{"nctId":"NCT00036855","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":["AIDS-related Peripheral/Systemic Lymphoma","AIDS-related Primary CNS Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent/Refractory Childhood Hodgkin Lymphoma"],"enrollment":36,"completionDate":""},{"nctId":"NCT00082836","phase":"NA","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-12","conditions":["Lymphoma"],"enrollment":10,"completionDate":""},{"nctId":"NCT00017381","phase":"EARLY_PHASE1","title":"Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":["Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Small Lymphocytic Lymphoma","Waldenström Macroglobulinemia"],"enrollment":30,"completionDate":""},{"nctId":"NCT00060294","phase":"PHASE1","title":"Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-04","conditions":["Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00902525","phase":"PHASE2","title":"Zevalin Twice in Aggressive Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie","startDate":"2008-01","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":25,"completionDate":"2011-09"},{"nctId":"NCT00397800","phase":"PHASE1,PHASE2","title":"Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Technical University of Munich","startDate":"2005-06","conditions":["Lymphoma"],"enrollment":12,"completionDate":"2013-05"},{"nctId":"NCT00772655","phase":"PHASE2","title":"Zevalin® First Line in Follicular Lymphoma","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":["Follicular Lymphoma"],"enrollment":60,"completionDate":"2015-06"},{"nctId":"NCT00463463","phase":"PHASE3","title":"Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2007-04","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00186589","phase":"PHASE1","title":"90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL","status":"COMPLETED","sponsor":"Stanford University","startDate":"2004-05","conditions":["Lymphoma, Non-Hodgkin","Blood and Marrow Transplant (BMT)"],"enrollment":30,"completionDate":"2007-07"},{"nctId":"NCT00058292","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2000-04","conditions":["Lymphoma"],"enrollment":44,"completionDate":"2009-03"},{"nctId":"NCT00514475","phase":"PHASE2","title":"Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2005-11","conditions":["Mantle Cell Lymphoma"],"enrollment":160,"completionDate":"2009-06"},{"nctId":"NCT00505232","phase":"PHASE2","title":"Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)","status":"COMPLETED","sponsor":"CABYC","startDate":"2006-01","conditions":["Mantle Cell Lymphoma"],"enrollment":30,"completionDate":"2011-05"},{"nctId":"NCT01479387","phase":"","title":"Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":["Non-Hodgkin's Lymphoma (NHL)"],"enrollment":72,"completionDate":"2011-02"},{"nctId":"NCT00038623","phase":"PHASE2","title":"Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-04","conditions":["Lymphoma, Mantle-Cell"],"enrollment":35,"completionDate":"2010-02"},{"nctId":"NCT00193505","phase":"PHASE2","title":"Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2003-10","conditions":["Non-Hodgkins Lymphoma"],"enrollment":40,"completionDate":"2005-08"},{"nctId":"NCT00193440","phase":"PHASE2","title":"Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2002-04","conditions":["Non-Hodgkins Lymphoma"],"enrollment":40,"completionDate":"2009-01"},{"nctId":"NCT00271050","phase":"PHASE1","title":"External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2005-12","conditions":["Lymphoma, B-Cell"],"enrollment":12,"completionDate":"2010-06"},{"nctId":"NCT00386321","phase":"PHASE2","title":"Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Chulalongkorn University","startDate":"2006-04","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":10,"completionDate":"2010-01"},{"nctId":"NCT01164696","phase":"","title":"A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":["Lymphoma, Follicular","Non-Hodgkin Lymphoma"],"enrollment":30,"completionDate":"2009-05"},{"nctId":"NCT01157988","phase":"PHASE2","title":"90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2007-01","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":20,"completionDate":""},{"nctId":"NCT00354822","phase":"PHASE2","title":"Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.","status":"TERMINATED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2005-08","conditions":["Lymphoma, Non-Hodgkin"],"enrollment":25,"completionDate":"2009-08"},{"nctId":"NCT00859001","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":["Follicular Lymphoma"],"enrollment":55,"completionDate":""},{"nctId":"NCT00850512","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":55,"completionDate":""}],"_emaApprovals":[{"date":"2004-01-16","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148737","MMSL":"17128","NDDF":"009576","UNII":"4Q52C550XK","VUID":"4021301","VANDF":"4021301","INN_ID":"7873","RXNORM":"262323","UMLSCUI":"C0877880","ChEMBL_ID":"CHEMBL2108667","KEGG_DRUG":"D04489","DRUGBANK_ID":"DB00078","PUBCHEM_CID":"74890578","SNOMEDCT_US":"385546007","IUPHAR_LIGAND_ID":"6777","MESH_SUPPLEMENTAL_RECORD_UI":"C422802"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2002-","companyName":"Spectrum Pharms","relationship":"Original Developer"}],"publicationCount":503,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"V10XX02","allCodes":["V10XX02"]},"biosimilarFilings":[],"originalDeveloper":"Spectrum Pharms","recentPublications":[{"date":"2026 Feb 26","pmid":"41746558","title":"Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.","journal":"EJNMMI radiopharmacy and chemistry"},{"date":"2025 Dec 3","pmid":"41130791","title":"Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal.","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"date":"2025 Apr 23","pmid":"40361339","title":"Assessing the Clinical Effectiveness of Radioimmunotherapy with Combined Radionuclide/Monoclonal Antibody Conjugates in Cancer Treatment: Insights from Randomised Clinical Trials.","journal":"Cancers"},{"date":"2024","pmid":"38464386","title":"Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.","journal":"Exploration of targeted anti-tumor therapy"},{"date":"2024 Apr 4","pmid":"38207010","title":"A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.","journal":"The oncologist"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"Spectrum Pharms","companyId":"spectrum-pharms","modality":"Monoclonal antibody","firstApprovalDate":"2002","aiSummary":"Zevalin (Ibritumomab Tiuxetan) is a CD20-directed Radiotherapeutic Antibody developed by Spectrum Pharmaceuticals. It targets B-lymphocyte antigen CD20, a protein found on the surface of B cells, and delivers a radioactive dose to these cells. Zevalin is approved for the treatment of Follicular non-Hodgkin's lymphoma and was first approved by the FDA in 2002. The commercial status of Zevalin is owned by Spectrum Pharmaceuticals, and its patented status is unknown. Key safety considerations include radiation exposure and potential side effects such as infusion reactions and hematologic toxicity.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2002-02-19T00:00:00.000Z","mah":"SPECTRUM PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":"2004-01-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}